A message from our partners at Paradigm Press Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.
Dear Reader,
As co-host of The Clay Travis & Buck Sexton Show… one of the most listened-to radio programs in the country… I’ve conducted a lot of important interviews over the years…
But I’ve never done anything like this.
Take a look.
As you’re about to hear… there’s a rapidly developing and massively critical situation quickly unfolding in the Trump Administration right now…
The mainstream media – and very few Americans know anything about this.
But what I believe Trump has up his sleeve could flood an estimated $2.2 trillion into a handful of little-known technology companies over the next decade…
And potentially spark a 40-year economic boom that reshapes this country from the ground up.
I believe this will make history.
I wouldn’t be doing my job if I didn’t come forward and explain what’s happening.
This may be the most important message I’ve ever shared.
Please take a moment to watch my interview now.
You’ll be so glad you did.
Buck Sexton
Former CIA Officer and Co-Host, The Clay & Buck Show
Further Reading from MarketBeat Media Why GRAIL Stock Could Be Biotech's Next Big BreakoutWritten by Bridget Bennett. Published 11/19/2025. 
Key Points - Insider buying is a reliable signal in market pullbacks, offering long-term confidence amid short-term volatility.
- Biotech stock GRAIL is one to watch, with its breakthrough cancer detection technology nearing FDA approval.
- Despite economic concerns, the American Dream is still attainable through long-term investing, saving, and strategic financial choices.
Retail investors are understandably on edge after recent sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we’re still in one of the best times in history to build wealth—especially if you think long-term and stick to time-tested principles. According to Green, this pullback isn't as severe as it may feel. "Just last Wednesday, the Dow hit an all-time high," he noted, explaining that recent selling pressure has more to do with valuation concerns and interest-rate doubts than any fundamental breakdown. Why the Market Pulled Back Jeff Brown recently traveled to a ghost town in the middle of an American desert…
To investigate what could be the biggest technology story of this decade.
In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom…
And only one company here in the U.S. can mine this obscure metal. Click here to get the details on this virtual monopoly. Green attributes the dip to two core concerns. First, investors are starting to question elevated tech and AI valuations, especially as earnings season brings those expectations into focus. Second, recent inflation data and slower hiring have softened hopes that the Fed will cut rates in December. With the central bank emphasizing a "data-dependent" posture, markets are less certain that relief is coming this year. Why Selling Now Might Be the Wrong Move Instead of trying to predict where things will be next week, Green encourages investors to zoom out. He calls himself "a long-term optimist" and points out that historically the market's trend is up and to the right. For traders, a little short-term caution might be warranted. But for long-term investors, these dips are often opportunities to buy high-quality stocks at more attractive prices. Insider Buying Can Point the Way One of the most reliable indicators in times like these is insider buying. Green suggests that when officers and directors—people with access to non-public financial information—put their own money into the company, it’s worth noting. He recommends tracking insider trading activity to see which stocks corporate executives are buying, not just selling. While insiders aren’t always right, their actions can serve as a useful signal when markets are in flux. A Biotech Breakout to Watch: GRAIL One sector Green is focused on right now is biotech, where artificial intelligence is helping accelerate drug development and reduce costs. He highlighted one company in particular: GRAIL (NASDAQ: GRAL). Spun off from Illumina, GRAIL has developed the Gallery Test, a blood-based assay that can detect more than 50 types of cancer from a single draw. Green has even used the test himself and calls it "a good feeling" to know you’re clear on so many deadly diseases—especially ones like pancreatic cancer that often go undetected until late stages. With FDA fast-track status and potential insurance reimbursement ahead, Green sees GRAIL’s roughly $3 billion market cap as just a starting point. The Biotech Risk—and Big Pharma's Appetite Of course, biotech comes with risk. Most drug candidates never make it through all three phases of clinical trials. Still, larger pharmaceutical companies like Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Bristol Myers (NYSE: BMY) are actively acquiring promising small caps to replace expiring patents. Green pointed to Johnson & Johnson (NYSE: JNJ) as a recent example. The company invested in a private firm's prostate cancer drug candidate before it received FDA approval—underscoring how aggressive Big Pharma can be when clinical trials look promising. Green believes biotech is especially compelling now because healthcare is recession-resistant. Whether the economy is growing or shrinking, people still seek treatment. For investors looking to weather volatility, sectors like healthcare, utilities, consumer staples, and food companies often offer steadier demand—and less of the extreme swings seen in some AI names. The American Dream Is Still Possible—But Mindset Matters Despite economic challenges, Green argues that the American Dream is far from dead. He wrote The American Dream to counter the narrative that it’s out of reach, noting he was surprised by polls showing nearly 70% of Americans believe it's no longer attainable. The reality, he says, is that with access to low-cost investment tools, no-commission trading, and widely available information, building wealth has never been more accessible. The challenge is knowing what to do—and having the discipline to do it. He breaks it down simply: if a 25-year-old invests $190 a month in an S&P 500 index fund, they could have $1 million by age 65—tax-free in a Roth IRA. No extreme frugality required. "You could eat out, take trips, and still build wealth," Green says—as long as you save and leave that money alone to compound. Creative Solutions for Today’s Housing Market Housing may feel out of reach, but Green says it doesn’t have to be. Mortgage rates have risen and prices are up since the pandemic—but there are still ways to get in. He shares his personal story of buying two houses with no money down by working directly with motivated sellers and assuming their mortgages—a method often called a "contract for deed." It might not land you the perfect home right away, but it can help you start building equity sooner than you think. Stay Focused on the Long Game Volatile markets come and go. What matters is how you respond. Whether it’s tracking insider moves, exploring high-upside sectors like biotech, or simply believing in your ability to build a financial future, Green’s message is clear: the American Dream is still within reach. You just have to keep your eyes on it—and take the next right step.
| 
